Refine Assumptions for Dividend and Retained Earnings
Forecast
Following are the income statement and balance sheet for Medtronic
PLC.
Consolidated Statement of Income ($ millions) For Fiscal Year Ended |
April 26, 2019 |
---|---|
Net sales | $30,557 |
Costs and expenses | |
Cost of products sold | 9,155 |
Research and development expenses | 2,330 |
Selling, general, and administrative expense | 10,418 |
Amortization of intangible assets | 1,764 |
Restructuring charges, net | 198 |
Certain litigation charges, net | 166 |
Other operating expense, net | 258 |
Operating profit (loss) | 6,268 |
Other nonoperating income, net | (373) |
Interest expense | 1,444 |
Income (loss) before income taxes | 5,197 |
Income tax provision | 547 |
Net income (loss) | 4,650 |
Net (income) loss attributable to noncontrolling interests | (19) |
Net income (loss) attributable to Medtronic | $ 4,631 |
Consolidated Balance Sheet ($ millions) | April 26, 2019 |
---|---|
Current assets | |
Cash and cash equivalents | $ 4,393 |
Investments | 5,455 |
Accounts receivable, less allowances of $190 | 6,222 |
Inventories, net | 3,753 |
Other current assets | 2,144 |
Total current assets | 21,967 |
Property, plant, and equipment, net | 4,675 |
Goodwill | 39,959 |
Other intangible assets, net | 20,560 |
Tax assets | 1,519 |
Other assets | 1,014 |
Total assets | $89,694 |
Current liabilities | |
Current debt obligations | $838 |
Accounts payable | 1,953 |
Accrued compensation | 2,189 |
Accrued income taxes | 567 |
Other accrued expenses | 2,925 |
Total current liabilities | 8,472 |
Long-term debt | 24,486 |
Accrued compensation and retirement benefits | 1,651 |
Accrued income taxes | 2,838 |
Deferred tax liabilities | 1,278 |
Other liabilities | 757 |
Total liabilities | 39,482 |
Shareholders' equity | |
Ordinary shares | 0 |
Additional paid-in capital | 26,532 |
Retained earnings | 26,270 |
Accumulated other comprehensive loss | (2,711) |
Total shareholders' equity | 50,091 |
Noncontrolling interests | 121 |
Total equity | 50,212 |
Total liabilities and shareholders' equity | $89,694 |
a. Use the financial statements along with the additional
information below to forecast retained earnings for the fiscal year
ended April 2020.
Forecasted net income to Medtronic shareholders for fiscal 2020 | $4,908 million |
Dividends to Medtronic shareholders in fiscal 2019 | 2,693 million |
Forecasted retained earnings $Answer million
b. Suppose the MD&A section of the Form 10-K and additional
guidance from the company reveals the following additional
information. “Ordinary cash dividends declared and paid totaled
50.0 cents per share for each quarter of fiscal year 2019.”
At year end April 26, 2019, the company had 1,340,697,595 shares
issued and outstanding. Use this information to refine your
forecast of retained earnings for the fiscal year ended April
2020.
Forecasted retained earnings $Answer million
Get Answers For Free
Most questions answered within 1 hours.